Jun Liu

TL;DR: The structure and evolution of chimeric antigen receptors are discussed, and the tools used for production of CAR-T cells are reported on, to address the challenges posed by the technology.

TL;DR: The treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications, however, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.

TL;DR: Therapy of B-ALL subjects relapsing post transplant with donor-derived CAR-T cells is safe and effective but associated with a high rate of CRS, which seems comparable to those achieved with alternative therapies but data from a randomized trial are lacking.

TL;DR: Treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL, though some cases quickly relapsed afterCAR-T cell treatment.

TL;DR: Pre preventive infusion of donor-derived CAR-T cells constructed using viral systems after haploidentical HSCT may be safe and that immunosuppressors may not affect the proliferation of CAR- T cells.